Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab

Authors:

Abstract
Sir, As a result of the introduction of new disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA), patients with refractory RA tend to be treated with an increasing number of different DMARDs, alone or in combination. This improves the chances of achieving good disease control but also risks triggering adverse reactions.